Failure of Bromocriptine, Dopamine, and Thyrotropin-Releasing Hormone to Affect Prolactin Secretion by Human Decidual Tissue in Vitro*

Golander, Avraham; Barrett, Janet R; Hurley, Thomas W.; Barry, Susan; Handwerger, Stuart

doi:10.1210/jcem-49-5-787

Cited by 86 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, it has been reported that PRL production in deciduous tissue cultures is not controlled by dopamine, and in particular, it is unaffected by BC. Thus, even when BC treatment continued to term, yielding low fetal and maternal blood PRL levels, amniotic fluid levels remain normal [15][16][17], There is a second theoretical risk: a possible effect of depressed maternal dopamine levels upon fetal development, e.g. in macroPROL not treated or treated for less than 4 weeks; this has not been considered, except during the first weeks of pregnancy [18].…”

Section: Discussionmentioning

confidence: 99%

Follow-Up of Children Born of Bromocriptine-Treated Mothers

Goldstein²,

et al. 1985

View full text Add to dashboard Cite

A survey carried out in France at the beginning of 1984 concerning development of children born of mothers treated with bromocriptine (BC) during part or all of the pregnancy showed the absence of any adverse effects of BC in 64 children born from 53 mothers. In 60 cases, BC was prescribed (2.5–7.5 mg/day) for hyperprolactinemia; 23 mothers were treated with BC for 4 weeks or less, and 23 others for 30 weeks or more. After a follow-up of between 6 months and 9 years, all children are normal. Psychological development in the 23 children born to mothers treated with BC during more than 30 weeks of pregnancy actually appears more precocious, with excellent scholastic performance in the oldest.

show abstract

Section: Discussionmentioning

confidence: 99%

Follow-Up of Children Born of Bromocriptine-Treated Mothers

Goldstein²,

et al. 1985

View full text Add to dashboard Cite

show abstract

“…6 In addition, oestrogen7 and vasoactive intestinal polypeptide (unpublished observation), both of which stimulate pituitary prolactin release, had no effect on the release of decidual prolactin.…”

Section: Decidual Prolactinmentioning

confidence: 93%

Paracrine and Autocrine Factors Involved in the Regulation of the Release of Human Decidual Prolactin and Human Placental Lactogen

Handwerger

Golander

Richards

et al. 1989

Placenta as a Model and a Source

Self Cite

View full text Add to dashboard Cite

During pregnancy, the decidua and placenta synthesise and secrete several protein hormones that have identical or nearly identical chemical and biological properties to protein hormones synthesised and secreted by the pituitary gland and other tissues. For example, human decidual tissue synthesises and releases protein hormones that are identical to pituitary prolactin 1 and ovarian relaxin. 2 The placenta synthesises and releases hCG and hPL which have striking chemical and biological similarities to LH and to growth hormone and prolactin, respectively.3 Nevertheless, despite the striking similarities between these hormones, the regulation of the synthesis and secretion of the protein hormones from the decidua and placenta is different from that of the pituitary protein hormones. Pituitary prolactin, growth hormone and most protein hormones are stored in large secretory granules, but ultrastructural and biochemical studies indicate that decidual prolactin 4 and hPL5 are localised in the postmicrosomal supernatants of decidual and placental tissue homogenates.We report here studies from our laboratory on the regulation of the synthesis and release of decidual prolactin and placental prolactin and present new evidence indicating novel regulatory pathways involved in the release of these hormones. Particular attention will be given to the role of autocrine and paracrine factors in the regulation of decidual prolactin. DECIDUAL PROLACTINOur initial studies of the synthesis and release of decidual prolactin indicated that TRH, dopamine, and bromocriptine had no effect on the synthesis or release of decidual prolactin, even at concentrations 1000 times the half-maximal concentrations that affect the synthesis and release of pituitary prolactin. 6 In addition, oestrogen7 and vasoactive intestinal polypeptide (unpublished observation), both of which stimulate pituitary prolactin release, had no effect on the release of decidual prolactin.Several studies subsequently demonstrated that exposure of endometrial tissue from the follicular phase of the menstrual cycle to progesterone resulted in decidualisation of the endometrium and in a striking increase in both the synthesis and release of prolactin. 8 Several investigators also observed that progesterone stimulated prolactin release from decidualised

show abstract

“…This process, known as decidualization, results in characteristic morphologic changes and the induction of prolactin, insulin-like growth factor binding protein 1 (IGFBP-1) and several other decidualization-specific genes. Numerous investigations indicate that the prolactin expressed in decidual cells is identical in sequence to that of pituitary prolactin (13) but that the factors that regulate the synthesis and release of decidual and pituitary prolactins are different (12,15). The differences in regulation are due in large part to the fact that decidual prolactin is regulated by an alternative promoter located 5' of an additional noncoding exon (exon la) located approximately 6 kilobases (kb) upstream of the pituitary prolactin transcription initiation site (9,16).…”

Section: Introductionmentioning

confidence: 99%

N5 endometrial stromal cell line: A model system to study decidual prolactin gene expression

Brar

Kanda

Kessler

et al. 1999

In Vitro Cell.Dev.Biol.-Animal

Self Cite

View full text Add to dashboard Cite

Prolactin gene expression in extrapituitary tissues, such as decidua and lymphocytes, is regulated by a distinct promoter approximately 6 kb upstream of the pituitary prolactin gene transcription start site. Here we describe studies in a human endometrial stromal cell line, N5, that was immortalized by transfection with an SV40 mutant and which expresses the prolactin gene driven by the extrapituitary promoter. The N5 cells have phenotypic features of primary cultures of decidualized human endometrial stromal cells and secrete low levels of prolactin and insulin-like growth factor binding protein-1 (IGFBP-1), both of which are markers of decidualized endometrial stromal cells. As in primary cultures of endometrial stromal cells, treatment of N5 cells with progesterone and estradiol alone or in combination with prostaglandin E2 stimulated the synthesis and release of prolactin. Transient transfection of the N5 cells with an expression vector containing - 2927/ + 66 bp of the decidual prolactin promoter coupled to a luciferase reporter gene resulted in a 20 to 25-fold increase in luciferase activity, a magnitude similar to that which occurs in primary cultures of endometrial stromal cells decidualized in vitro by treatment with progesterone and estradiol. Luciferase expression levels were similar in untreated N5 cells and N5 cells treated with progesterone and estradiol. Taken together, these results indicate that the N5 human endometrial stromal cell line has phenotypic characteristics of normal decidualized stromal cells and is a useful model to study regulation of decidual prolactin gene expression.

show abstract

Failure of Bromocriptine, Dopamine, and Thyrotropin-Releasing Hormone to Affect Prolactin Secretion by Human Decidual Tissue in Vitro*

Cited by 86 publications

References 17 publications

Follow-Up of Children Born of Bromocriptine-Treated Mothers

Follow-Up of Children Born of Bromocriptine-Treated Mothers

Paracrine and Autocrine Factors Involved in the Regulation of the Release of Human Decidual Prolactin and Human Placental Lactogen

N5 endometrial stromal cell line: A model system to study decidual prolactin gene expression

Contact Info

Product

Resources

About